FFA
STLN

Farther Finance Advisors’s Starling Oncology STLN Stock Holding History

Farther Finance Advisors’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38 Hold
7
– – ﹤0.01% 5871
2026
Q1 		$22 Buy
+7
New +$21 ﹤0.01% 5643

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Farther Finance Advisors's STLN Position: Q2 2026 in Review

Farther Finance Advisors held its Starling Oncology (STLN) position steady in Q2 2026 at 7 shares worth $38. The position accounts for ﹤0.01% of the portfolio, ranked #5871.

Farther Finance Advisors first reported a position in STLN in Q1 2026 and has held it in 2 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Farther Finance Advisors held 7 shares of Starling Oncology worth $38 as of Q2 2026.
  • Farther Finance Advisors left its Starling Oncology share count unchanged in Q2 2026.
  • Starling Oncology made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #5871 holding.
  • Farther Finance Advisors first reported a position in Starling Oncology in Q1 2026 and has held it in 2 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.